Combined with more extensive brain sampling and better clinical and radiological assessment came the realisation that there were other conditions, some age-related, that revealed HP-tau either in a different chemical composition to that seen in AD (such as AGD and ARTAG) or in a different neuroanatomical distribution from AD (such as CTE) or without the corresponding second Aβ pathology, as seen in AD (such as PART). The gene discussed is MAPT; the disease is Alzheimer disease.